Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IXchange: Vilobelimab for ANCA-Associated Vasculitis
NCT03895801Phase 2Completed
- Sponsor
- InflaRx
- Start
- Apr 2019
- Primary completion
- Apr 2021
- Modality
- Monoclonal Antibodies
- Countries
- 11
01
Overview
Phase 2, randomised, double-blind trial of vilobelimab in granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA) (3 arms), sponsored by InflaRx. Primary endpoint: Percentage of Subjects Achieving Clinical Response at Week 16. Started Apr 2019; status: completed.
02
Drugs
vilobelimab
03
Conditions
granulomatosis with polyangiitis (GPA)microscopic polyangiitis (MPA)
Beyond the preview
Go deeper on NCT03895801.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03895801.